about
Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st centuryDuffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibilityMinimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig ModelDevelopment of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxisHenipavirus neutralising antibodies in an isolated island population of African fruit batsPlanning for the unexpected: Ebola virus, Zika virus, what's next?Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studiesCoreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.Single domain antibody multimers confer protection against rabies infection.Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro.A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in AfricaMonoclonal antibodies for prophylactic and therapeutic use against viral infections.Association between active GB virus-C (hepatitis G) infection and HIV-1 disease in Uganda.HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor.Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison.Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses.Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit.Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells.Characterization of an influenza virus pseudotyped with Ebolavirus glycoprotein.Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses.Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.Generation of Arctic-like Rabies Viruses Containing Chimeric Glycoproteins Enables Serological Potency StudiesTechnical considerations for the generation of novel pseudotyped virusesDemonstration of Viral Antibodies by Pseudotype Virus NeutralizationCurrent progress with serological assays for exotic emerging/re-emerging virusesHuman papilloma virus genotype distribution and risk factor analysis amongst reproductive-age women in urban GambiaIdentification of Broad-Spectrum Antiviral Compounds by Targeting Viral EntryBats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EUA Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
P50
Q21092294-AEC5D87A-8CB2-442A-8817-B1D1ADFF7573Q24657233-59D6C142-62D9-45B3-A199-A5825F879CF4Q28553683-2DF6C3CF-B1CC-43F7-8521-712E4B321291Q28601417-85C3272C-4112-41FB-987C-1E686D36B1E8Q28732845-4B7484D4-2A20-4A8C-80DA-08A5A54F1D4AQ30240131-85E060DD-BC47-47DC-A2C7-4FAB15663E80Q33914496-1A0EA7F0-F323-4568-BD26-7D8AD92EA11AQ33927434-3B81F047-0085-4E29-8178-CF7F7AA30A19Q34971008-2AF3FF5D-6872-4499-B447-10E107A294CEQ35605579-4A5931FC-5789-4657-BF1A-DCDEB5C89DCAQ36788708-D5681D4E-C109-4311-807E-88123C062405Q37336363-BE109011-C6E4-4FC0-B392-8580A2636171Q37461555-AF7D8349-3F70-49D2-AF31-F413595A69C5Q38078178-36B3F248-4125-4078-BE47-4D1B8C0139F8Q38878059-3372C334-F0BE-4758-B51D-1E6B5E274DF1Q39944408-3320D458-3D26-4EF5-9121-0EBCF450CDF2Q39946439-79226E78-4195-486F-ADE4-A70233D3B3E6Q41525616-FEEE4F41-5AFB-4A36-9AD2-24FF2DBEC530Q41714726-634DA407-6A5A-4F85-9127-0A871F8BA1B0Q44106386-0726EEC4-6636-4545-A7A3-4345CCCF0EAFQ44526948-88B94B19-6A92-49AA-9178-707D8EC843F0Q45323703-A13F8C20-D67C-4389-B8FC-81C849F3EAEEQ45372329-D6BEA02E-4F3C-4050-85B0-E3DA4ED83914Q47558239-03E26B89-AAD7-4BD3-9DE4-93EE92E32BB2Q56881314-23F328BA-3415-4838-93DE-1C2ED5C0722FQ57275154-98FE0C7C-D388-4700-8EBC-1880002EFDE4Q57275155-78F41859-077D-4FB2-9C52-5DA07589353AQ57275156-C568CCC5-BA12-44F1-ACB3-FB441009BCC4Q57290326-D0876976-BD13-4CAB-A2A1-0DBCCC35EB37Q62485484-B4D380C4-8785-4AED-BCF9-2FBCD1955982Q64231999-D85304FF-CF2C-4E64-8AC4-4A1917189D2EQ95828155-C4E46056-2CD5-453C-9FB7-FEEDFA22A7DA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Edward Wright
@ast
Edward Wright
@en
Edward Wright
@es
Edward Wright
@nl
Edward Wright
@sl
type
label
Edward Wright
@ast
Edward Wright
@en
Edward Wright
@es
Edward Wright
@nl
Edward Wright
@sl
prefLabel
Edward Wright
@ast
Edward Wright
@en
Edward Wright
@es
Edward Wright
@nl
Edward Wright
@sl
P106
P1153
57060626300
P1960
BbZfXykAAAAJ
P21
P31
P496
0000-0001-7041-5138